Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical pain management products developer Adolor Corporation has signed a two-year agreement to co-promote GlaxoSmithKline's anti-thrombotic agent Arixtra in the US.
Subscribe to our email newsletter
Adolor will begin the recruitment process to hire 30 surgeon-focused sales representatives to collaborate with GlaxoSmithKline sales representatives in a combined national effort to co-promote Arixtra (fondaparinux sodium).
Under the terms of the agreement, GlaxoSmithKline will provide cost reimbursement to Adolor for its promotion of Arixtra.
This collaborative sales force could also potentially focus on Adolor’s lead product candidate Entereg (alvimopan), an investigational peripherally-acting mu opioid receptor antagonist currently under FDA review.
“Arixtra is an important medical option for the prevention and treatment of deep vein thrombosis and pulmonary embolism,” stated Kevin Lokay, vice president of GlaxoSmithKline Oncology and Acute Care. “Aligning and integrating the Adolor and GSK sales forces will expand our reach with Arixtra while paving the way for future collaboration in the surgical market.”
Adolor is also developing a sterile lidocaine patch, which is in phase II clinical development for post-incisional pain and has a number of discovery research programs focused on the identification of novel compounds for the treatment of pain.